4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A 2 and its receptor

Oncogene

Volumn 30, Issue 1, 2011, Pages 106-116

  Huang, R Y ^a   Li, M Y ^a   Hsin, M K Y ^a   Underwood, M J ^a   Ma, L T ^a   Mok, T S K ^a   Warner, T D ^b   Chen, G G ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

cell proliferation; CREB; lung cancer; NNK; thromboxane A2

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FUREGRELATE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE B2; THROMBOXANE SYNTHASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; CELL SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SMOKING;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; APOPTOSIS; CARCINOGENS; CELL GROWTH PROCESSES; CELL SURVIVAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYDRAZINES; LUNG NEOPLASMS; NITROSAMINES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SMOKING; THROMBOXANE A2; THROMBOXANE-A SYNTHASE; TUMOR CELLS, CULTURED;

EID: 78650980124     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.390     Document Type: Article

References (47)

1. Aggarwal S, Kim SW, Ryu SH, Chung WC, Koo JS. (2008). Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein. Cancer Res 68: 981-988.
2. Amin S, Desai D, Hecht SS, Hoffmann D. (1996). Synthesis of tobacco-specific N-nitrosamines and their metabolites and results of related bioassays. Crit Rev Toxicol 26: 139-147.
3. Aronov AM, Baker C, Bemis GW, Cao J, Chen G, Ford PJ et al. (2007). Flipped out: structure-guided design of selective pyrazolyl-pyrrole ERK inhibitors. J Med Chem 50: 1280-1287.
4. Cailleteau C, Liagre B, Battu S, Jayat-Vignoles C, Beneytout JL. (2008). Increased cyclooxygenase-2 and thromboxane synthase expression is implicated in diosgenin-induced megakaryocytic differentiation in human erythroleukemia cells. Anal Biochem 380: 26-34.
5. Calapai G, Caputi AP, Mannucci C, Gregg EO, Pieratti A, Aurora Russo G et al. (2009). A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal Toxicol 21: 1138-1143.
6. 0Byrne KJ, Pidgeon GP. (2010). The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochim Biophys Acta 1805: 153-166.
7. Chen GG, Lee TW, Yip JH, Xu H, Lee IK, Mok TS et al. (2006). Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. Cancer Lett 234: 193-198.
8. Ciani E, Guidi S, Bartesaghi R, Contestabile A. (2002). Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J Neurochem 82: 1282-1289.
9. 2 on some isolated smooth muscle preparations. Br J Pharmacol 73: 773-778.
10. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ. (1999). Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59: 4574-4577.
11. De Leval X, Dassesse T, Dogne JM, Waltregny D, Bellahcene A, Benoit V et al. (2006). Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. J Pharmacol Exp Ther 318: 1057-1067.
12. El-Bayoumy K, Iatropoulos M, Amin S, Hoffmann D, Wynder EL. (1999). Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet. Cancer Res 59: 1400-1403.
13. Ermert L, Dierkes C, Ermert M. (2003). Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 9: 1577-1578.
14. Fahn HJ, Wang LS, Kao SH, Chang SC, Huang MH, Wei YH. (1998). Smoking-associated mitochondrial DNA mutations and lipid peroxidation in human lung tissues. Am J Respir Cell Mol Biol 19: 901-909.
15. Grozio A, Catassi A, Cavalieri Z, Paleari L, Cesario A, Russo P. (2007). Nicotine, lung and cancer. Anticancer Agents Med Chem 7: 461-466.
16. Hecht SS. (2002). Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 3: 461-469.
17. Hoffmann D, Brunnemann KD, Prokopczyk B, Djordjevic MV. (1994). Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. J Toxicol Environ Health 41: 1-52.
18. Huang JS, Ramamurthy SK, Lin X, Le Breton GC. (2004). Cell signalling through thromboxane A2 receptors. Cell Signal 16: 521-533.
19. Hung YH, Hung WC. (2009). 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) enhances invasiveness of lung cancer cells by up-regulating contactin-1 via the alpha7 nicotinic acetylcholine receptor/ERK signaling pathway. Chem Biol Interact 179: 154-159.
20. Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T et al. (1997). Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 18: 795-799.
21. Kim Y, Chongviriyaphan N, Liu C, Russell RM, Wang XD. (2006). Combined antioxidant (beta-carotene, alpha-tocopherol and ascorbic acid) supplementation increases the levels of lung retinoic acid and inhibits the activation of mitogen-activated protein kinase in the ferret lung cancer model. Carcinogenesis 27: 1410-1419.
22. Laag E, Majidi M, Cekanova M, Masi T, Takahashi T, Schuller HM. (2006). NNK activates ERK1/2 and CREB/ATF-1 via b-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer 119: 1547-1552.
23. Leung KC, Hsin MK, Chan JS, Yip JH, Li M, Leung BC et al. (2009). Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. Exp Cell Res 315: 2974-2981.
24. Li MY, Hsin MK, Yip J, Mok TS, Underwood MJ, Chen GG. (2010). PPAR{gamma} activation extinguishes smoking carcinogen by inhibiting NNK-mediated proliferation. Am J Respir Cell Mol Biol 42: 113-122.
25. Li MY, Yip J, Hsin MK, Mok TS, Wu Y, Underwood MJ et al. (2008). Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis. Eur Respir J 32: 911-923.
26. Li X, Tai HH. (2009). Activation of thromboxane A (2) receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells. Carcinogenesis 30: 1606-1613.
27. Li X, Wei J, Tai HH. (2007). Activation of extracellular signal-regulated kinase by 12-hydroxy- heptadecatrienoic acid in prostate cancer PC3 cells. Arch Biochem Biophys 467: 20-30.
28. Lu G, Liao J, Yang G, Reuhl KR, Hao X, Yang CS. (2006). Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosa-mino)-1-(3-pyridyl)- 1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res 66: 11494-11501.
29. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. (2007). Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 97: 368-377.
30. McLemore TL, Hubbard WC, Litterst CL, Liu MC, Miller S, McMahon NA et al. (1988). Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 48: 3140-3147.
31. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E et al. (2006). Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor. Purinergic Signal 2: 627-632.
32. Miggin SM, Kinsella BT. (2001). Thromboxane A (2) receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells. Biochim Biophys Acta 1539: 147-162.
33. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
34. Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV et al. (2008b). Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res 68: 4097-4104.
35. Moussa O, Riker JM, Klein J, Fraig M, Halushka PV, Watson DK. (2008a). Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 27: 55-62.
36. Nakahata N. (2008). Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 118: 18-35.
37. Nie D, Che M, Zacharek A, Qiao Y, Li L, Li X et al. (2004). Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol 164: 429-439.
38. Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K et al. (2000). Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 267: 245-251.
39. Nishioka T, Guo J, Yamamoto D, Chen L, Huppi P, Chen CY. (2010). Nicotine, through upregulating pro-survival signaling, cooperates with NNK to promote transformation. J Cell Biochem 109: 152-161.
40. Parsons A, Daley A, Begh R, Aveyard P. (2010). Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. Br Med J 340: b5569.
41. Proulx LI, Gaudreault M, Turmel V, Augusto LA, Castonguay A, Bissonnette EY. (2005). 4-(Methylnitrosamino)-1-(3-pyridyl)-1-bu-tanone, a component of tobacco smoke, modulates mediator release from human bronchial and alveolar epithelial cells. Clin Exp Immunol 140: 46-53.
42. Sakai H, Suzuki T, Takahashi Y, Ukai M, Tauchi K, Fujii T et al. (2006). Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett 580: 3368-3374.
43. Sakamoto KM, Frank DA. (2009). CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res 15: 2583-2587.
44. Sebolt-Leopold JS, Herrera R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947.
45. Stoimenov I, Helleday T. (2009). PCNA on the crossroad of cancer. Biochem Soc Trans 37: 605-613.
46. Wei J, Yan W, Li X, Chang WC, Tai HH. (2007). Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells. Biochem Pharmacol 74: 787-800.
47. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM et al. (2003). Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111: 81-90.